anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Cognitive deficits were related to Spinocerebellar Ataxia type 3/Machado-Joseph Disease (SCA3/MJD), but the Cerebellar Cognitive Affective Syndrome (CCAS) needs further investigation in this disorder. We aimed to characterize cognitive-affective deficits in manifest and premanifest SCA3/MJD carriers.
METHODS: Subjects at 50% risk, manifest carriers and unrelated controls were evaluated in-person or in virtual settings with CCAS Scale (CCAS-S), Stroop Color-Word Test (SCWT), Trail-Making Test (TMT), and Reading the Mind in the Eyes Test (RMET). Scale for Assessment and Rating of Ataxia (SARA) >2.5 or Friedreich Ataxia Rating Scale/Activities of Daily Living (FARS-adl) >4 divided carriers into manifest and premanifest. Time after onset or time left to gait ataxia onset (TimeToAfterOnset) were estimated. Differences between groups and correlations with TimeToAfterOnset, SARA and FARS-adl were checked.
RESULTS: After random selection to balance groups, 23 manifest and 35 premanifest carriers, and 58 controls were included. CCAS-S, semantic fluency, phonemic fluency, category switching, affect, SCWT, and RMET showed significant differences between manifest carriers and controls; premanifest carriers mostly displayed intermediate values between controls and manifest carriers. These variables correlated with TimeToAfterOnset and SARA scores of the carriers. Correlations with SARA were stronger in the pre-ataxic group. CCAS-S had the strongest correlations with time and SARA.
DISCUSSION: Cognitive-affective deficits in SCA3/MJD involve executive function, language, affect, and social cognition, which seem to be altered prior to the ataxia onset, and correlate with markers of motor progression. CCAS-S was the most promising biomarker and should be evaluated in longitudinal studies.
The data will be extracted from medical records of all people who are at least one year after a stroke, live in the community and are insured by Health maintenence Organization (HMO).In the first part we expect to extract data of approximately 40,000 patients . In the second part, a sub sample of 240 patients will be recruited to answer standardized questionnaires. In the third part, a sub-sample from part 2, of 20 people will be interviewed.
A high through-put screening method for identifying agents effective for inhibiting biofilm formation and/or killing established biofilm are disclosed. The method includes three tiers, and each tier includes three specific biological process assays. The tier levels are a primary screen, a confirmation screen, and a dose-response screen, and the biological process assays include assays for total bacterial growth, bacterial metabolic activity, and biofilm formation. The series of assays may be run once or more than once at each tier. A library of compounds is subject to tier A and only compounds meeting a primary parameter advance to tier B, and only tier B compounds meeting a confirmation parameter advance to tier C, and only tier C compounds meeting a dose-response parameter are identified as putative agents effective for inhibiting and/or eradicating a biofilm, further wherein the assays are conducted for each compound subject to the respective tier. The method is effective and validated for identifying agents which inhibit and/or kill  Staphylococcus epidermidis, Pseudomonas aeruginosa , and  Acinetobacter baumannii  biofilms. Agents identified according to the high through-put screen and validated in follow-up experiments as effective for inhibiting and/or killing bacterial biofilms are also disclosed.
Ictal epileptic headache, characterized by headache as the sole symptom of a seizure attack, is a rare condition. In this case report, we present a 52-year-old female with a history of systemic lupus erythematosus who sought medical attention at the headache clinic due to a new type of headache. The headache was described as an intense painful wave followed by a dull headache, without autonomic symptoms or migrainous features. Magnetic resonance imaging revealed an enhancing lesion in the left hippocampus in addition to two other lesions in the corpus callosum and left parieto-occipital lobe. Electroencephalography during the headache episodes showed epileptic discharges originating from the left fronto-temporal region. The patient was initiated on levetiracetam, which resulted in the resolution of both the epileptic discharges and the headaches. This case underscores the significance of considering ictal epileptic headache as a potential secondary cause for headaches, particularly in patients with underlying conditions that may predispose them to epilepsy, such as systemic lupus erythematosus.
Participants receive Placebo Solution for Injection, via subcutaneous injection up to 10 mL. Injection treatment will occur once every 4 weeks for up to 6 treatments.
The study hypothesis is that the prevalence of obstructive sleep apnea in patients presenting for total knee or total hip arthroplasty is higher than generally suspected. The study will include just one arm and results will be compared to a literature control group, a study performed by Harrison et al. and published in the December 2003 issue of The Journal of Arthroplasty. Participants referred for preoperative evaluation will be screened using a standard questionnaire. Those at high risk of obstructive sleep apnea will then undergo a formal overnight sleep study (polysomnography). The Berlin questionnaire is being used for screening.
The invention provides a medicine used for specifically intervening the adhesion and infiltration of circulating tumor cell in blood into peripheral tissues, and a novel method for applying the medicine in preventing mammalian patient primary tumor re-metastasis after surgical resection. Compared with anticancer medicines, the medicine has low toxic and side effect, and can be taken for a long time by a patient. A half-life period in blood is long, such that frequent administration is not needed. The medicine can be taken before a tumor surgery or in an early stage after a tumor surgery (at least 5 years), and assists in passing a tumor metastasis high-risk period. The medicine provided by the invention can be used as a single medicine, and can be applied in combination with other medicines for comprehensively controlling each link of tumor metastasis. The medicine can also be used in combination with antitumor medicines for assisting cancer treatment. With the medicine, a market gap of medicines used for preventing tumor metastasis after surgery can be filled.
Patients receive pirtobrutinib PO QD on days 1-28 of each cycle and receive venetoclax PO QD on days 1-28 of cycles 2-20. Cycles repeat every 28 days for up to 20 cycles in the absence of disease progression or unacceptable toxicity. Patients who experience disease progression within 12 months of stopping combination treatment may receive pirtobrutinib PO QD in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo blood sample collection, bone marrow aspiration and biopsy and CT throughout the study.
PURPOSE: To obtain a composite material having a liquid crystal structure of an amphoteric surfactant, etc., water, an oil (A) and a higher fatty acid, and obtain a composition having excellent maintenance of makeup and excellent water resistance, sweat resistance and resistance to sebum by dispersing an oil (B) and powder, etc., into the composite material. CONSTITUTION: This composite material contains an amphoteric surfactant and/or a semipolar surfactant, water, a hydrocarbon oil, an oil (A) such as a silicone oil and a higher fatty acid (e.g. oleic acid). Mixing ratio of the surfactant and the higher fatty acid is 1:1-1:3 in a molar ratio, the oil (A) is 1-15wt.% and water is >=50wt.%. A polymeric silicone oil and/or an oil (B) such as a fluorine oil and powder (e.g. talc) in an amount of <=30wt.% are subjected to coexistence and dispersed into the resultant composite material to prepare the objective composition. This composite material has a liquid crystal structure of reverse-hexagonal type exhibiting water-repelling property.
PROBLEM TO BE SOLVED: To provide a kit for diagnosis which enables the diagnosing specific liver diseases. SOLUTION: A human serum containing antibodies which recognize cytochrome P450 derived from humans is used as a sample for diagnosing hepatitis type C and alcoholic cirrhosis in this kit. A measuring method of the concentration of cytochrome P450 in human serum for this diagnosis proceeds as follows. (1) After a human serum, which is a sample, is added to solid supporting material which directly or indirectly unites with antibodies which recognize cytochrome P450 derived from humans so that an antigen-antibody reaction occurs, excess cytochrome P450 derived from humans and substances which have not reacted are washed and removed. (2) After this, labeled antibodies which recognize cytochrome P450 derived from humans are added to this reactant so that an antigen-antibody reaction occurs.  And then, excess labeled antibodies which recognize cytochrome P450 derived from humans are washed and removed. (3) Next to this, cytochrome P450 in the human serum is detected on the basis of the labels of the labeled antibodies of this reactant.
Participants who are in Hot-Plus group will divide several small groups which will be 4 persons with mild cognitive impairment. Participants will receive computerized virtual reality training program by Hot-Plus as a group activity for one hour, once a week for 12 weeks.
PURPOSE: An antipyretic injection solution containing healthy soy sauce as an active ingredient is provided to enhance immunity and to ensure excellent antipyretic and detoxifying effects. CONSTITUTION: A method for manufacturing an antipyretic injection solution comprises: a step of preparing a meju(Korean fermented soybean lump) using Rhynchosia volubilis and wheat flour; a step of maturing the meju and preparing healthy soy sauce; and a step of filtering the healthy soy sauce with a microfilter. The method for also comprises a step of mixing 100 parts by weight of the healthy soy sauce and 1-20 parts by weight of one or more extracts selected from the group consisting of an antler extract, an apricot seed extract, an aromatic tree extract, and a wood-cultivated ginseng extract. Bamboo salt water is prepared by dissolving 20-30 parts by weight of bamboo salt in 100 parts by weight of a nutrient solution. The nutrient solution is prepared by mixing 5-10 parts by weight of sulfur-containing duck, 5-10 parts by weight of garlic, and 3-5 parts by weight of Ulmus pumila in 100 parts by weight of water, and boiling at 90-110 deg. C for 20-28 hours.
AIM: Tirzepatide, a dual agonist of glucagon-like peptide receptor and glucose-dependent insulinotropic polypeptide receptor, is expected to exhibit high clinical efficacy in obese type 2 diabetic patients. We evaluated the effects of tirzepatide on pancreatic β-cells and the liver, an insulin-target organ, in a mouse model of obese type 2 diabetes mellitus.
MATERIALS AND METHODS: Obese type 2 diabetic db/db mice (BKS.Cg-/+ Leprdb/+ Leprdb/Jcl*) were used in this study. Starting at 7 weeks of age, mice were treated with tirzepatide (30 nmol/kg, subcutaneous injection twice a week) or semaglutide (200 nmol/kg, subcutaneous injection twice a week). The control group received phosphate-buffered saline (40-50 μL/subcutaneous injection twice a week). After 4 weeks of drug administration, pancreatic β-cells and the liver were removed and examined.
RESULTS: Compared to the control group, blood glucose and body weight were significantly reduced in the group that received either tirzepatide or semaglutide (p < 0.001 and p < 0.05, respectively). Fasting insulin was significantly higher in the semaglutide and tirzepatide groups compared to the control group (p < 0.001). β-Cell mass and quality of insulin granules in β-cells similarly increased in the semaglutide and tirzepatide groups compared to the control group (p < 0.05 and p < 0.001, respectively). The fat staining area in the liver in oil red O staining and the liver-spleen ratio in computed tomography showed improvement only in the tirzepatide group (p < 0.001 and p < 0.005, respectively). Liver macrophage M1/M2 ratio similarly improved with semaglutide and tirzepatide (p < 0.05).
CONCLUSION: Tirzepatide and semaglutide exhibited similar potent glucose-lowering effects. At concentrations used in the present experiments, tirzepatide exhibited more beneficial effects on β-cell-related gene expression, insulin granule count and glucose-stimulated insulin secretion compared to semaglutide. In addition, tirzepatide exhibited a stronger favourable effect on hepatic fat deposition and improved inflammation in the liver. This is the first report showing that tirzepatide, a novel diabetes drug, exhibits a superior effect on pancreatic β-cells and the liver of obese type 2 diabetic mice.
Facilitating viewer comparison of a plurality of medical images of at least one body part on a softcopy review workstation is described. First and second medical images are displayed such that the second medical image appears as a spatially registered underlay to the first medical image exposed through an aperture therein. The aperture comprises at least one edge that is viewer-manipulable in a back-and-forth manner so that the first and second medical images can be visually compared with minimal eye movement. For a temporal comparison embodiment, the first and second medical images comprise identical views of the same body part acquired at different times. For a cross-modality comparison embodiment, the first and second medical images are acquired substantially concurrently, or at different times, using different medical imaging modalities. For a bilateral comparison embodiment, the first and second images are corresponding views of two laterally corresponding body parts.
Collected, primary resources enabled us to extract data that are scarcely present in medical literature of the two Breslauer morphologists of both the human body and - metaphorically - the society: Wilhelm Ebstein (1836-1912) and Sigismund Asch (1825-1901), particularly the latter, who described morphology of melanosis in his doctoral dissertation in 1846, to switch on reshaping social morphology of Wrocław (Breslau) in Virchow-like manner. In contrast to the main perspective of Ebstein's anomaly that has been finely described in past biographical papers, a primary aspect of infectious diseases is highlighted here in Ebstein's heritage. In 1869, his habilitation on recurrent typhus provided professional support for Asch. As Ebstein cared for the poor in shelters of Wrocław, Asch admitted poor patients from early morning hours to gain such a great esteem to be elected alderman. Asch's mentality corresponded to Ferdinand Lassalle's philosophy of the social democratic movement. In front of cholera epidemics, Asch contributed to medical control of meat, development of city canalization, establishment of green areas as well he deeply got involved in charity institutions for widows and orphans and was a model medical doctor to follow for much more famous Janusz Korczak who perished together with children from his orphanage in Nazi Concentration Camp in Treblinka. Asch was immortalized as "Doctor Klaus" in the popular play by Adolf L'Arronge and united people in progress from feudal discrimination to democracy and in fight for civil rights in industrial society to gradually replace aristocracy with meritocracy in the mainstream of development of modern society.
The perception of taking a generic, relative to brand, medication has been demonstrated to exacerbate the nocebo effect. Conversely, positive attribute framing has been shown to attenuate the nocebo effect. However, little is known about the longevity of positive attribute framing nor how it interacts with generic versus brand treatment cues. Healthy participants (N = 205) were randomised to receive either sham-modafinil capsules with a brand or generic appearance, in conjunction with standard negative side effect framing (brand-negative: N = 42; generic-negative: N = 41) or positive side effect framing (brand-positive: N = 40; generic-positive: N = 40). The remainder were randomised to a no-treatment control (N = 42). Participants were informed that modafinil could enhance alertness and cognitive performance and reduce fatigue. Critically, modafinil was described as having several potential side effects. Treatment-related side effects, alertness, fatigue and cognitive performance were measured at baseline, 30-min post-treatment and 24 h later. Nocebo and placebo effects were observed across modafinil-treated participants relative to control. Positive framing significantly reduced warned side effects for 24 h. Perceived side effect likelihood, severity, and worry mediated the nocebo, but not framing, effect. Results have important implications for the presentation of side effect information, providing a potential route to reduce unwanted negative effects of generic medication.
Group 1 (split-dose PEG regimen; Colyte, Taejoon Pharmaceuticals, Seoul, Korea; 236g PEG, 22.74g Na2SO4, 6.74g NaHCO3, 5.86g NaCl, and 2.97g KCl) ingested 2 liters of PEG at 6 PM on the day before the procedure and the remaining 2 liters in the early morning at least 2 hours prior to the procedure. Patients were instructed to take PEG 250 ml every ten minutes.
To improve the MRI workflow, a recommender system is provided, comprising an input unit, a processing unit and an output unit. The input unit is configured to receive data including information regarding a plurality of pre-tests and associated pre-test results provided to a patient. The plurality of pre-tests are performed prior to an MRI scan session. The plurality of pre-tests includes: cognitive tests, sensorimotor tests, or combinations thereof. The processing unit is configured to generate a cognitive profile of the patient based on the received data, the profile indicating a pattern of relative dominance and difficulty of the individual in several cognitive domains. The processing unit is further configured to determine a task implementation of an MRI scan session based on a cognitive profile of the patient. The processing unit is further configured to provide a suggestion of the determined task implementation for the MRI scan session via the output unit.
INTRODUCTION: The melting temperature (Tm) mapping method (TM) identifies bacterial species by intrinsic patterns of Tm values in the 16S ribosomal RNA gene (16S rDNA) extracted directly from whole blood. We examined potential clinical application of TM in children with bloodstream infection (BSI).
METHODS: This was a prospective observational study at a children's hospital in Japan from 2018 to 2021. In patients with diagnosed or suspected BSI, we investigated the match rates of pathogenic bacteria identified by TM and blood culture (BC), the inspection time to identification of TM, and the amount of bacterial DNA in blood samples.
RESULTS: The median age of 81 patients (93 samples) was 3.6 years. Of 23 samples identified by TM, 11 samples matched the bacterial species with BC (positive-match rate, 48 %). Of 64 TM-negative samples, 62 samples were negative for BC (negative-match rate, 97 %). Six samples, including one containing two pathogenic bacterial species, were not suitable for TM identification. In total, the matched samples were 73 of 93 samples (match rate, 78 %). There were seven samples identified by TM in BC-negative samples from blood collected after antibiotic therapy. Interestingly, the bacteria were matched with BC before antibiotic administration. These TM samples contained as many 16S rDNA copies as the BC-positive samples. The median inspection time to identification using TM was 4.7 h.
CONCLUSIONS: In children with BSI, TM had high negative-match rates with BC, the potential to identify the pathogenic bacteria even in patients on antibiotic therapy, and more rapid identification compared to BC.
REGISTERING CLINICAL TRIALS: UMIN000041359https://center6.umin.ac.jp/cgi-open-bin/ctr/ctr_view.cgi?recptno=R000047220.
Intervention arm B: Lactating women (LW) randomized in this arm will receive ready-to-use nutritional supplement, 'Balanced energy-protein (BEP)' for next 6 months to be consumed in a dose of 2 sachets of 75 grams per day. Further, LW will also receive standard of care which comprises of standard nutritional counseling, key messages of exclusive breastfeeding, essential newborn and infant care and immunization.
Disclosed is a gynecopathy external use washing lotion and a preparation method thereof. The invention relates to a pharmaceutical composition and a preparation method thereof. The washing lotion contains the following components: Callicarpa nudiflora, senecio, radix sophorae falvescentis, stemona, broom cypress fruit, common cnidium fruit, borneol, chlorhexidine acetate and essence. The preparation method comprises the steps of extraction of the above-mentioned components, alcohol precipitation and preparation. The beneficial effects of the invention are as follows: the washing lotion prepared in the invention has no side effects to human bodies and shows good effects on sterilization and detoxification; a small quantity of safe and effective western medicinal components are used as accessories to the washing lotion, which endows the washing location with characteristics of safety, rapidness and efficiency. The preparation method provided in the invention abandons the conventional process of hot reflux extraction of traditional Chinese medicinal materials and has the advantages of a short preparation time, low energy consumption and high extraction efficiency, and is favorable for protecting environment and saving cost.
A consequence of chronic kidney disease is anemia due to decreased production of erythropoietin. Anemia is associated with decreased oxygen delivery and utilization, and can result in fatigue, lethargy, decreased cognition and mental acuity, and cardiac complications.This study was designed to compare 2 dosing regimens, once every-2-weeks and once every-4-weeks with the once-weekly dosing regimen. Men and women who are diagnosed with anemia associated with chronic kidney disease will participate in this study. Approximately 400 patients will be included. This is a randomized (patients are assigned different treatments based on chance), open-label, multicenter study of epoetin alfa in patients who are not on dialysis and who are already maintaining anemia with epoetin alfa administered once weekly. The study is 40 to 42 weeks in duration. All eligible patients will be treated with epoetin alfa according to one of the following 3 regimens: once-a-week injection (Group 1), or once every-2-weeks injection (Group 2), or once every-4-weeks injection (Group 3). The maximum volume per injection will not be more than 1 mL, therefore some patients may receive more than one injection per dose. The study treatment includes a period to convert to the new dosing regimen, and a subsequent stable maintenance treatment period. After the initial dose, hemoglobin will be measured on a weekly basis and used to determine adjustments in dose for each patient. The primary hypothesis is that the average change in hemoglobin level in the groups that received epoetin alfa once every 2 weeks or once every 4 weeks is not lower than the change in hemoglobin level in the group that received epoetin alfa only once a week. Adverse events will be monitored throughout the study. Clinical laboratory examinations, vital signs, and physical examinations will be conducted routinely to ensure patient safety. Approximately 1 mL of epoetin alfa will be injected under the skin either once a week, once every 2 weeks, or once every 4 weeks (maximum doses of 20,000 IU once a week, 40, 000 IU every 2 weeks, or 80,000 IU every 4 weeks, respectively) for up to 36 weeks of treatment.